Quantbot Technologies LP Makes New $34,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 959 shares of the company’s stock, valued at approximately $34,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State of New Jersey Common Pension Fund D acquired a new position in shares of Dyne Therapeutics during the third quarter worth about $1,588,000. Seven Eight Capital LP increased its position in shares of Dyne Therapeutics by 195.7% in the 2nd quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock valued at $1,896,000 after purchasing an additional 35,568 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after purchasing an additional 19,730 shares in the last quarter. Mutual of America Capital Management LLC purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter worth $1,724,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Dyne Therapeutics during the second quarter worth $676,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $29.50 on Friday. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of -8.29 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1-year low of $10.33 and a 1-year high of $47.45. The firm’s fifty day moving average price is $31.12 and its 200 day moving average price is $35.37.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on DYN shares. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Piper Sandler reiterated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, Stifel Nicolaus raised their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.82.

Insiders Place Their Bets

In other news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. This trade represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,257 shares of company stock worth $6,193,718. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.